bioAffinity Technologies Expands Diagnostic Division with Promotions and New Hires to Strengthen Clinical BenchBusiness Wire • 12/15/22
bioAffinity Technologies Presents Proprietary Cancer Therapeutic Research at Joint ASCB-EMBO MeetingBusiness Wire • 12/01/22
bioAffinity Technologies Reports Third Quarter 2022 Financial Results and Provides Business UpdateBusiness Wire • 11/14/22
bioAffinity Technologies Announces Sheila Habib, MD and David Hill, MD Join the Company's Scientific and Medical Advisory BoardBusiness Wire • 11/10/22
bioAffinity Technologies Announces Award of Therapeutic Patents in China, Mexico and AustraliaBusiness Wire • 10/25/22
bioAffinity Technologies Presents Results from Flow Cytometry Analysis of the Lung at CHEST ConferenceBusiness Wire • 10/12/22
bioAffinity Technologies Receives Additional $7.7M from Exercise of Warrants, Total Capital from Public Offering Increases to Approximately $15.6MBusiness Wire • 09/28/22
bioAffinity Technologies Publishes Peer-Reviewed Results of High-Throughput Flow Cytometry Use for Evaluating Lung Health in PLOS ONEBusiness Wire • 09/14/22
WallachBeth Capital Announces Closing Of bioAffinity Technologies, Inc. $7.8 Million Initial Public OfferingPRNewsWire • 09/06/22
bioAffinity Technologies, Inc. Announces Closing of $7.8 Million Initial Public OfferingBusiness Wire • 09/06/22